News – AKL Therapeutics

APPA Phase 2a results published in Osteoarthritis & Cartilage

The leading international journal in this field, Osteoarthritis & Cartilage, has published the paper “The efficacy and safety of a fixed-dose combination of apocynin and paeonol, APPA, in symptomatic knee OA: A double-blind, randomized, placebo-controlled, clinical trial”. Asger Reinstrup Bihlet, Inger Byrjalsen, Jeppe Ragnar Andersen, Alan Reynolds, Nicholas Larkins, Peter Alexandersen, Helene Rovsing, Robert Moots […]

Anti-Inflammatory Activity of APPA in Human Chondrocytes

A peer reviewed paper on a study analyzing the capacity of APPA to modulate the inflammatory response induced by IL-1β in human articular chondrocytes and cartilage has been published in the Pharmaceuticals Journal. The paper was authored by Mercedes Fernández-Moreno, Tamara Hermida-Gómez, Nicholas Larkins, Alan Reynolds and Francisco Blanco. Pharmaceuticals 2024, 17(1), 118; https://doi.org/10.3390/ph17010118. Full text of the […]

List of Peer Reviewed Papers, Abstracts & Posters

1. Fernández-Moreno M, Hermida-Gómez T, Larkins N, Reynolds A, Blanco FJ. Anti-Inflammatory Activity of APPA (Apocynin and Paeonol) in Human Articular Chondrocytes. Pharmaceuticals. 2024; 17(1):118. https://doi.org/10.3390/ph17010118 2. Fernandez-Moreno M, Hermida Gómez T, Larkins N, Reynolds A, Blanco-Garcia F. Effect of APPA (combination of apocynin and paeonol) compound on cellular senescence using human articular chondrocytes. Osteoarthritis and […]

APPA Shows Promise in Age Related Diseases

New data presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggests that AKL Therapeutics’ investigational oral osteoarthritis (OA) drug APPA may have a dual effect on senescence – a process in which cells stop dividing as a natural consequence of ageing. Senescence plays a major role in the development of many […]

Interview with Longevity Technology

Osteoarthritis affects one in seven adults in the US, with more than half of patients of working age. There are currently no effective and well tolerated oral therapies that provide long term relief for the symptoms of OA or reduce its progression. With APPA, AKL believes it has the only drug with a mechanism of action […]

OARSI 2023 Presentation

AKL’s data on the effect of APPA in reducing cellular senescence in articular chondrocytes conducted by INIBIC (Instituto de Investigación Biomédica de A Coruña) has been published at OARSI 2023, the leading global osteoarthritis conference being held in Denver, Colorado. Copy of the poster is avaliable – please click here. OARSI is a key congress […]